Leishmaniasis patients in Eastern Africa may soon benefit from a new drug set to be developed by collaboration of Novartis, one of the biggest pharmaceuticals company and the Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research and development organization.
By Mekonnen Teshome – Kampala, Ugannda – Scientists working for the Drugs for Neglected Diseases initiative (DNDi) say that they are conducting research and clinical trials to find safer, efficacious and more patient friendly treatment for various Neglected Tropical Diseases (NTD).